We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


ClearLight Licenses Rights from Stanford University

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ClearLight Licenses Rights from Stanford University"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

ClearLight Diagnostics, LLC announced that it has signed an exclusive, worldwide license agreement with Stanford University.  The license agreement provides exclusive intellectual property rights covering inventions relating to a new microscopy approach called SPED (SPherical-aberration-assisted Extended Depth-of-field) light sheet microscopy as well as for a new RNA interrogation technology developed for multiplexed, volumetric visualization of both long and short RNAs in a variety of intact tissues.

SPED is a conceptually distinct microscopy approach which turns spherical aberration into an advantage by combining the large volumetric field of view of an extended depth of field with the optical sectioning of light sheet microscopy, thereby eliminating the need to physically scan the detection objective for volumetric imaging while maintaining spatial resolution. At the core of SPED light sheet microscopy is a unique and scalable method for extending the depth of field, by building upon the optical mechanisms that induce spherical aberrations. 

The RNA interrogation technology licensed by ClearLight is a versatile, high- content, and scalable molecular phenotyping technology of intact tissues that retains RNAs in clarified tissue, coupled with amplification tools for multiplexed detection. Nucleic acid labeling in CLARITY processed tissue may represent an important scientific and clinical opportunity, enabling detection of not only diverse coding RNA variants but also non-coding RNAs. The resulting technology enables measurement of activity- dependent transcriptional signatures, cell-identity markers, and diverse non-coding RNAs in rodent and human tissue volumes. 

"We are excited to add these important technologies to our portfolio related to the 3-dimensional interrogation and imaging of tissue samples," said Sarah McCurdy, CEO of ClearLight. "We continue to develop a set of valuable tools and capabilities to support our product development of the CLARITY process."


Story from ClearLight Diagnostics. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.